You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorthalidone
Accession NumberDB00310  (APRD00127)
TypeSmall Molecule
GroupsApproved
DescriptionA benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. [PubChem]
Structure
Thumb
Synonyms
1-keto-3-(3'-Sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-oxo-3-(3-Sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
2-chloro-5-(1-Hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-Hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
3-(4'-chloro-3'-Sulfamoylphenyl)-3-hydroxyphthalimidine
3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
Chlorphthalidolone
Chlortalidone
Chlorthalidone
Phthalamodine
Phthalamudine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorthalidonetablet50 mgoralAa Pharma Inc1976-12-31Not applicableCanada
Chlorthalidone 100mg Tabletstablet100 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Chlorthalidone 50mg Tabletstablet50 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Chlorthalidone Tab 100mgtablet100 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Chlorthalidone Tab 100mgtablet100 mgoralPro Doc Limitee1978-12-311999-08-12Canada
Chlorthalidone Tab 50mgtablet50 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Chlorthalidone Tab 50mgtablet50 mgoralPro Doc Limitee1978-12-311999-08-12Canada
Hygroton 50mgtablet50 mgoralNovartis Pharmaceuticals Canada Inc1968-12-311999-08-04Canada
Novo-thalidone Tab 100mgtablet100 mgoralNovopharm Limited1975-12-312005-08-10Canada
Novo-thalidone Tab 50mgtablet50 mgoralNovopharm Limited1975-12-312005-08-10Canada
Thalitonetablet15 mg/1oralMonarch Pharmaceuticals, Inc1988-12-20Not applicableUs
Uridon Tab 100mgtablet100 mgoralIcn Canada Ltd.1970-12-312005-04-26Canada
Uridon Tab 50mgtablet50 mgoralIcn Canada Ltd.1974-12-312005-04-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Chlorthalidone Tab 100mgtablet100 mgoralApotex Inc1976-12-31Not applicableCanada
Chlorthalidonetablet25 mg/1oralMylan Institutional Inc.2013-05-03Not applicableUs
Chlorthalidonetablet50 mg/1oralA S Medication Solutions1981-02-26Not applicableUs
Chlorthalidonetablet25 mg/1oralKAISER FOUNDATION HOSPITALS2009-06-08Not applicableUs
Chlorthalidonetablet50 mg/1oralAphena Pharma Solutions Tennessee, Llc1981-02-26Not applicableUs
Chlorthalidonetablet25 mg/1oralPhysicians Total Care, Inc.2003-06-09Not applicableUs
Chlorthalidonetablet50 mg/1oralMylan Pharmaceuticals Inc.1981-02-26Not applicableUs
Chlorthalidonetablet25 mg/1oralSun Pharmaceutical Industries, Inc.2016-02-12Not applicableUs
Chlorthalidonetablet25 mg/1oralA S Medication Solutions Llc1981-02-26Not applicableUs
Chlorthalidonetablet25 mg/1oralPd Rx Pharmaceuticals, Inc.2009-11-18Not applicableUs
Chlorthalidonetablet25 mg/1oralMylan Pharmaceuticals Inc.1981-02-26Not applicableUs
Chlorthalidonetablet50 mg/1oralSun Pharmaceutical Industries, Inc.2016-02-12Not applicableUs
Chlorthalidonetablet50 mg/1oralA S Medication Solutions Llc1981-02-26Not applicableUs
Chlorthalidonetablet25 mg/1oralbryant ranch prepack1981-02-26Not applicableUs
Chlorthalidonetablet25 mg/1oralRebel Distributors Corp2009-11-18Not applicableUs
Chlorthalidonetablet25 mg/1oralA S Medication Solutions1981-02-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HygrotonNovartis
SaluretinBalkanpharma
Brand mixtures
NameLabellerIngredients
Apo-atenidoneApotex Inc
Atenolol and ChlorthalidoneMylan Pharmaceuticals Inc.
ClorpresMylan Pharmaceuticals Inc.
Combipres 0.1/15 TabBoehringer Ingelheim (Canada) Ltd Ltee
EdarbyclorTakeda Pharmaceuticals America, Inc.
Ntp-atenolol/chlorthalidoneTeva Canada Limited
TenoreticAstra Zeneca Pharmaceuticals Lp
Tenoretic 100/25mg TabAstrazeneca Canada Inc
Tenoretic 50/25mg TabAstrazeneca Canada Inc
Teva-atenolol/chlorthalidoneTeva Canada Limited
SaltsNot Available
Categories
UNIIQ0MQD1073Q
CAS number77-36-1
WeightAverage: 338.766
Monoisotopic: 338.012805247
Chemical FormulaC14H11ClN2O4S
InChI KeyInChIKey=JIVPVXMEBJLZRO-UHFFFAOYSA-N
InChI
InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
IUPAC Name
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoindoles and derivatives
Sub ClassIsoindolines
Direct ParentIsoindolones
Alternative Parents
Substituents
  • Isoindolone
  • Benzenesulfonamide
  • Isoindole
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
PharmacodynamicsChlorthalidone, a monosulfonamyl diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Chlorthalidone is used alone or with atenolol in the management of hypertension and edema.
Mechanism of actionChlorthalidone inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Chlorthalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism.
Related Articles
AbsorptionAbsorbed relatively rapidly after oral administration.
Volume of distributionNot Available
Protein bindingHigh (75% [58% to albumin])
Metabolism

Liver

Route of eliminationThe major portion of the drug is excreted unchanged by the kidneys.
Half life40 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea, weakness, dizziness and disturbances of electrolyte balance.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Chlorthalidone Action PathwayDrug actionSMP00122
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.5447
Caco-2 permeable-0.6272
P-glycoprotein substrateNon-substrate0.767
P-glycoprotein inhibitor INon-inhibitor0.9603
P-glycoprotein inhibitor IINon-inhibitor0.9573
Renal organic cation transporterNon-inhibitor0.891
CYP450 2C9 substrateNon-substrate0.6403
CYP450 2D6 substrateNon-substrate0.822
CYP450 3A4 substrateNon-substrate0.6369
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9299
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8193
Ames testNon AMES toxic0.7277
CarcinogenicityNon-carcinogens0.5752
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8623 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9968
hERG inhibition (predictor II)Non-inhibitor0.8914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Clonmel healthcare ltd
  • Ivax pharmaceuticals inc
  • Kv pharmaceutical co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pioneer pharmaceuticals inc
  • Pliva inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Sanofi aventis us llc
  • Monarch pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral50 mg
Tabletoral
Tabletoral15 mg/1
Prices
Unit descriptionCostUnit
Tenoretic 100 100-25 mg tablet2.91USD tablet
Tenoretic 100 tablet2.91USD tablet
Tenoretic 50 50-25 mg tablet2.18USD tablet
Tenoretic 50 tablet2.07USD tablet
Thalitone 15 mg tablet1.55USD tablet
Chlorthalidone 100 mg tablet1.07USD tablet
Chlorthalidone 50 mg tablet0.46USD tablet
Chlorthalidone 25 mg tablet0.28USD tablet
Apo-Chlorthalidone 50 mg Tablet0.13USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7157584 No2005-05-222025-05-22Us
US7572920 No2005-01-072025-01-07Us
US9066936 No2008-03-262028-03-26Us
US9169238 No2010-02-252030-02-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point239 °CPhysProp
water solubility120 mg/L (at 20 °C)MERCK INDEX (1996)
logP0.85BERTHOD,A ET AL. (1999)
Predicted Properties
PropertyValueSource
Water Solubility0.0528 mg/mLALOGPS
logP1.27ALOGPS
logP1.6ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)8.58ChemAxon
pKa (Strongest Basic)-2.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area109.49 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity81.3 m3·mol-1ChemAxon
Polarizability31.23 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Graf, W., Schmid, E. and Stoll, W.G.; US Patent 3,055,904; September 25,1962; assigned
to Geigy Chemical Corporation.

General ReferencesNot Available
External Links
ATC CodesC03EA06C03BB04C03BA04
AHFS Codes
  • 40:28.24
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Chlorthalidone.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Chlorthalidone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Chlorthalidone.
AcebutololChlorthalidone may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetazolamide.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorthalidone.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Chlorthalidone can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Chlorthalidone.
AlclometasoneAlclometasone may increase the hypokalemic activities of Chlorthalidone.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.
AldosteroneAldosterone may increase the hypokalemic activities of Chlorthalidone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorthalidone.
AlfuzosinAlfuzosin may increase the hypotensive activities of Chlorthalidone.
AliskirenChlorthalidone may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Chlorthalidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorthalidone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorthalidone.
AlprenololChlorthalidone may increase the hypotensive activities of Alprenolol.
AmbrisentanChlorthalidone may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Chlorthalidone.
AmifostineChlorthalidone may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amiloride.
AmlodipineChlorthalidone may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
AmoxapineAmoxapine may increase the hyponatremic activities of Chlorthalidone.
Amyl NitriteThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amyl Nitrite.
Anisotropine MethylbromideThe serum concentration of Chlorthalidone can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Apraclonidine.
ApremilastThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Chlorthalidone.
ArformoterolArformoterol may increase the hypokalemic activities of Chlorthalidone.
AripiprazoleAripiprazole may increase the hypotensive activities of Chlorthalidone.
AtenololChlorthalidone may increase the hypotensive activities of Atenolol.
Atracurium besylateThe serum concentration of Chlorthalidone can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Chlorthalidone can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Azilsartan medoxomil.
BalsalazideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Chlorthalidone.
BarbitalBarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Chlorthalidone.
BenactyzineThe serum concentration of Chlorthalidone can be increased when it is combined with Benactyzine.
BenazeprilChlorthalidone may increase the hypotensive activities of Benazepril.
BendroflumethiazideChlorthalidone may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Chlorthalidone.
BenoxaprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Chlorthalidone can be increased when it is combined with Benzatropine.
BepridilChlorthalidone may increase the hypotensive activities of Bepridil.
BetamethasoneBetamethasone may increase the hypokalemic activities of Chlorthalidone.
BetaxololBetaxolol may increase the hypotensive activities of Chlorthalidone.
BethanidineBethanidine may increase the hypotensive activities of Chlorthalidone.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorthalidone.
BimatoprostChlorthalidone may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Chlorthalidone can be increased when it is combined with Biperiden.
BisoprololChlorthalidone may increase the hypotensive activities of Bisoprolol.
BosentanChlorthalidone may increase the hypotensive activities of Bosentan.
BretyliumChlorthalidone may increase the hypotensive activities of Bretylium.
BrimonidineChlorthalidone may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Chlorthalidone.
BromfenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Chlorthalidone.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Chlorthalidone.
BumetanideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bumetanide.
BupranololChlorthalidone may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorthalidone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorthalidone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Chlorthalidone.
CandesartanChlorthalidone may increase the hypotensive activities of Candesartan.
CandoxatrilChlorthalidone may increase the hypotensive activities of Candoxatril.
CaptoprilChlorthalidone may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorthalidone.
CaroxazoneCaroxazone may increase the hypotensive activities of Chlorthalidone.
CarprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Carprofen.
CarteololChlorthalidone may increase the hypotensive activities of Carteolol.
CarvedilolChlorthalidone may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Chlorthalidone.
CelecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Celecoxib.
CeliprololChlorthalidone may increase the hypotensive activities of Celiprolol.
ChloroquineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Chloroquine.
ChlorothiazideChlorthalidone may increase the hypotensive activities of Chlorothiazide.
ChlorphenoxamineThe serum concentration of Chlorthalidone can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Chlorthalidone.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorthalidone.
CilazaprilChlorthalidone may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the hyponatremic activities of Chlorthalidone.
ClenbuterolClenbuterol may increase the hypokalemic activities of Chlorthalidone.
ClevidipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clevidipine.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Chlorthalidone.
ClocortoloneClocortolone may increase the hypokalemic activities of Chlorthalidone.
ClomipramineClomipramine may increase the hyponatremic activities of Chlorthalidone.
ClonidineChlorthalidone may increase the hypotensive activities of Clonidine.
ClonixinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorthalidone.
ColesevelamColesevelam can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Chlorthalidone.
CryptenamineChlorthalidone may increase the hypotensive activities of Cryptenamine.
CyclopentolateThe serum concentration of Chlorthalidone can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cyclophosphamide.
CyclothiazideChlorthalidone may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with D-Limonene.
DapagliflozinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the hyponatremic activities of Chlorthalidone.
DarifenacinThe serum concentration of Chlorthalidone can be increased when it is combined with Darifenacin.
DebrisoquinChlorthalidone may increase the hypotensive activities of Debrisoquin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Chlorthalidone.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Chlorthalidone.
DeserpidineChlorthalidone may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Deslanoside.
DesloratadineThe serum concentration of Chlorthalidone can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Chlorthalidone.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Chlorthalidone.
DexamethasoneDexamethasone may increase the hypokalemic activities of Chlorthalidone.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Chlorthalidone.
DexetimideThe serum concentration of Chlorthalidone can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorthalidone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorthalidone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorthalidone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorthalidone.
DiazoxideDiazoxide may increase the hypotensive activities of Chlorthalidone.
DiazoxideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Diclofenamide.
DicyclomineThe serum concentration of Chlorthalidone can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Chlorthalidone.
DiflunisalThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Chlorthalidone.
DifluprednateDifluprednate may increase the hypokalemic activities of Chlorthalidone.
DigitoxinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorthalidone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorthalidone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorthalidone.
DiltiazemChlorthalidone may increase the hypotensive activities of Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorthalidone.
DipivefrinDipivefrin may increase the hypokalemic activities of Chlorthalidone.
DipyridamoleThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dipyridamole.
DobutamineDobutamine may increase the hypokalemic activities of Chlorthalidone.
DofetilideChlorthalidone may increase the QTc-prolonging activities of Dofetilide.
DorzolamideChlorthalidone may increase the hypotensive activities of Dorzolamide.
DoxazosinChlorthalidone may increase the hypotensive activities of Doxazosin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorthalidone.
DroxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Chlorthalidone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorthalidone.
DuloxetineChlorthalidone may increase the orthostatic hypotensive activities of Duloxetine.
EfonidipineChlorthalidone may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorthalidone.
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Chlorthalidone.
EnalaprilChlorthalidone may increase the hypotensive activities of Enalapril.
EnalaprilatChlorthalidone may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Chlorthalidone.
EpinephrineEpinephrine may increase the hypokalemic activities of Chlorthalidone.
EpirizoleThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Epirizole.
EplerenoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Eplerenone.
EpoprostenolChlorthalidone may increase the hypotensive activities of Epoprostenol.
EprosartanChlorthalidone may increase the hypotensive activities of Eprosartan.
EquileninEquilenin may increase the hypokalemic activities of Chlorthalidone.
EquilinEquilin may increase the hypokalemic activities of Chlorthalidone.
EscitalopramEscitalopram may increase the hyponatremic activities of Chlorthalidone.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorthalidone.
EstroneEstrone may increase the hypokalemic activities of Chlorthalidone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Etacrynic acid.
EtanerceptThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Chlorthalidone.
EthopropazineThe serum concentration of Chlorthalidone can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorthalidone.
EtodolacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Chlorthalidone.
EtoricoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorthalidone.
Evening primrose oilThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Chlorthalidone.
exisulindThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with exisulind.
FelodipineChlorthalidone may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Chlorthalidone.
FenoldopamChlorthalidone may increase the hypotensive activities of Fenoldopam.
FenoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Chlorthalidone.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorthalidone.
FesoterodineThe serum concentration of Chlorthalidone can be increased when it is combined with Fesoterodine.
FloctafenineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Chlorthalidone.
FlumethasoneFlumethasone may increase the hypokalemic activities of Chlorthalidone.
FlunisolideFlunisolide may increase the hypokalemic activities of Chlorthalidone.
FlunixinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Chlorthalidone.
FluocinonideFluocinonide may increase the hypokalemic activities of Chlorthalidone.
FluocortoloneFluocortolone may increase the hypokalemic activities of Chlorthalidone.
FluorometholoneFluorometholone may increase the hypokalemic activities of Chlorthalidone.
FluoxetineFluoxetine may increase the hyponatremic activities of Chlorthalidone.
FluprednideneFluprednidene may increase the hypokalemic activities of Chlorthalidone.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Chlorthalidone.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Chlorthalidone.
FlurbiprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Chlorthalidone.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Chlorthalidone.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Chlorthalidone.
FormoterolFormoterol may increase the hypokalemic activities of Chlorthalidone.
FosinoprilChlorthalidone may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Chlorthalidone.
FurosemideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Furosemide.
Gallamine TriethiodideThe serum concentration of Chlorthalidone can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorthalidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Chlorthalidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorthalidone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorthalidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorthalidone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorthalidone.
GlycopyrroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Glycopyrronium.
GuanabenzChlorthalidone may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Chlorthalidone.
GuanethidineChlorthalidone may increase the hypotensive activities of Guanethidine.
GuanfacineChlorthalidone may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorthalidone.
HexamethoniumChlorthalidone may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
HMPL-004The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Chlorthalidone can be increased when it is combined with Homatropine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Chlorthalidone.
HydralazineChlorthalidone may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideChlorthalidone may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorthalidone.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Chlorthalidone.
HydroflumethiazideChlorthalidone may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorthalidone.
HyoscyamineThe serum concentration of Chlorthalidone can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Icatibant.
IloprostIloprost may increase the hypotensive activities of Chlorthalidone.
IndacaterolIndacaterol may increase the hypokalemic activities of Chlorthalidone.
IndalpineIndalpine may increase the hyponatremic activities of Chlorthalidone.
IndapamideChlorthalidone may increase the hypotensive activities of Indapamide.
IndenololChlorthalidone may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indoprofen.
IndoraminChlorthalidone may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorthalidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Chlorthalidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorthalidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Chlorthalidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorthalidone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorthalidone.
Ipratropium bromideThe serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium bromide.
IproclozideIproclozide may increase the hypotensive activities of Chlorthalidone.
IproniazidIproniazid may increase the hypotensive activities of Chlorthalidone.
IrbesartanChlorthalidone may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Chlorthalidone.
IsoetarineIsoetarine may increase the hypokalemic activities of Chlorthalidone.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Chlorthalidone.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Mononitrate.
IsoxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Chlorthalidone.
IvabradineChlorthalidone may increase the arrhythmogenic activities of Ivabradine.
KebuzoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorthalidone.
KetoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketorolac.
LabetalolChlorthalidone may increase the hypotensive activities of Labetalol.
LacidipineChlorthalidone may increase the hypotensive activities of Lacidipine.
LatanoprostChlorthalidone may increase the hypotensive activities of Latanoprost.
LeflunomideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Leflunomide.
LercanidipineChlorthalidone may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Levobunolol.
LevodopaChlorthalidone may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorthalidone.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Chlorthalidone.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorthalidone.
LicoriceLicorice may increase the hypokalemic activities of Chlorthalidone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorthalidone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Chlorthalidone.
LisinoprilChlorthalidone may increase the hypotensive activities of Lisinopril.
LithiumChlorthalidone may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorthalidone.
LofexidineChlorthalidone may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lornoxicam.
LosartanChlorthalidone may increase the hypotensive activities of Losartan.
LoxoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Chlorthalidone.
LumiracoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lumiracoxib.
MacitentanChlorthalidone may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Magnesium salicylate.
ManidipineChlorthalidone may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mannitol.
MasoprocolThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Chlorthalidone.
MecamylamineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mecamylamine.
MecamylamineMecamylamine may increase the hypotensive activities of Chlorthalidone.
Meclofenamic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Chlorthalidone.
Mefenamic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Chlorthalidone.
MeloxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorthalidone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorthalidone.
MethanthelineThe serum concentration of Chlorthalidone can be increased when it is combined with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Methazolamide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Chlorthalidone.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorthalidone.
MethyldopaChlorthalidone may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Chlorthalidone.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Chlorthalidone.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Chlorthalidone.
MetipranololChlorthalidone may increase the hypotensive activities of Metipranolol.
MetixeneThe serum concentration of Chlorthalidone can be increased when it is combined with Metixene.
MetolazoneChlorthalidone may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Chlorthalidone.
MibefradilChlorthalidone may increase the hypotensive activities of Mibefradil.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorthalidone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Chlorthalidone.
MilnacipranMilnacipran may increase the hyponatremic activities of Chlorthalidone.
MinaprineMinaprine may increase the hypotensive activities of Chlorthalidone.
MinoxidilChlorthalidone may increase the hypotensive activities of Minoxidil.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Chlorthalidone.
MoclobemideMoclobemide may increase the hypotensive activities of Chlorthalidone.
MoexiprilChlorthalidone may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Chlorthalidone.
MometasoneMometasone may increase the hypokalemic activities of Chlorthalidone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorthalidone.
MoxonidineChlorthalidone may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Chlorthalidone can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nabumetone.
NadololChlorthalidone may increase the hypotensive activities of Nadolol.
NaftifineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorthalidone.
NaproxenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Chlorthalidone.
NCX 4016The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with NCX 4016.
NebivololChlorthalidone may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Chlorthalidone.
NicardipineChlorthalidone may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Chlorthalidone.
NifedipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nifedipine.
Niflumic AcidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Niflumic Acid.
NiguldipineChlorthalidone may increase the hypotensive activities of Niguldipine.
NilvadipineChlorthalidone may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nimesulide.
NimodipineChlorthalidone may increase the hypotensive activities of Nimodipine.
NisoldipineChlorthalidone may increase the hypotensive activities of Nisoldipine.
NitrendipineChlorthalidone may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitroglycerin.
NitroprussideChlorthalidone may increase the hypotensive activities of Nitroprusside.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Chlorthalidone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorthalidone.
NVA237The serum concentration of Chlorthalidone can be increased when it is combined with NVA237.
ObinutuzumabChlorthalidone may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Chlorthalidone.
OlanzapineOlanzapine may increase the hyponatremic activities of Chlorthalidone.
OlmesartanOlmesartan may increase the hypotensive activities of Chlorthalidone.
OlodaterolOlodaterol may increase the hypokalemic activities of Chlorthalidone.
OlopatadineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olsalazine.
OmapatrilatChlorthalidone may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorthalidone.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Chlorthalidone.
OrgoteinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Chlorthalidone can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Oxcarbazepine.
OxprenololChlorthalidone may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Chlorthalidone can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorthalidone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorthalidone.
OxyphenbutazoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Chlorthalidone can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Pancuronium.
PapaverineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Papaverine.
ParamethasoneParamethasone may increase the hypokalemic activities of Chlorthalidone.
ParecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Parecoxib.
PargylineChlorthalidone may increase the hypotensive activities of Pargyline.
ParoxetineParoxetine may increase the hyponatremic activities of Chlorthalidone.
PenbutololChlorthalidone may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorthalidone.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
PentoliniumChlorthalidone may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Chlorthalidone.
PerindoprilChlorthalidone may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorthalidone.
PhenelzinePhenelzine may increase the hypotensive activities of Chlorthalidone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Chlorthalidone.
PheniprazinePheniprazine may increase the hypotensive activities of Chlorthalidone.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
PhenoxybenzamineChlorthalidone may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Chlorthalidone.
PhentolamineChlorthalidone may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Chlorthalidone.
PimecrolimusThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pimecrolimus.
PinacidilChlorthalidone may increase the hypotensive activities of Pinacidil.
PindololChlorthalidone may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorthalidone.
PipecuroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Chlorthalidone.
PirenzepineThe serum concentration of Chlorthalidone can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Chlorthalidone.
PiroxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Chlorthalidone.
PolythiazideChlorthalidone may increase the hypotensive activities of Polythiazide.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorthalidone.
PrazosinChlorthalidone may increase the hypotensive activities of Prazosin.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Chlorthalidone.
PrednisolonePrednisolone may increase the hypokalemic activities of Chlorthalidone.
PrednisonePrednisone may increase the hypokalemic activities of Chlorthalidone.
PregnenolonePregnenolone may increase the hypokalemic activities of Chlorthalidone.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Chlorthalidone.
ProcaterolProcaterol may increase the hypokalemic activities of Chlorthalidone.
ProcyclidineThe serum concentration of Chlorthalidone can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Propacetamol.
PropanthelineThe serum concentration of Chlorthalidone can be increased when it is combined with Propantheline.
PropranololChlorthalidone may increase the hypotensive activities of Propranolol.
PTC299The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quetiapine.
QuinaprilChlorthalidone may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Chlorthalidone can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Chlorthalidone.
RamiprilRamipril may increase the hypotensive activities of Chlorthalidone.
RasagilineRasagiline may increase the hypotensive activities of Chlorthalidone.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorthalidone.
RemikirenRemikiren may increase the hypotensive activities of Chlorthalidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorthalidone.
RescinnamineChlorthalidone may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Chlorthalidone.
ResveratrolThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Chlorthalidone.
RiociguatChlorthalidone may increase the hypotensive activities of Riociguat.
RisperidoneChlorthalidone may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may increase the hypokalemic activities of Chlorthalidone.
RituximabChlorthalidone may increase the hypotensive activities of Rituximab.
RofecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorthalidone.
SafrazineSafrazine may increase the hypotensive activities of Chlorthalidone.
SalbutamolSalbutamol may increase the hypokalemic activities of Chlorthalidone.
SalicylamideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Chlorthalidone.
SalsalateThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salsalate.
SaprisartanChlorthalidone may increase the hypotensive activities of Saprisartan.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Chlorthalidone.
ScopolamineThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
SelegilineSelegiline may increase the hypotensive activities of Chlorthalidone.
SelexipagChlorthalidone may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Chlorthalidone.
SildenafilSildenafil may increase the antihypertensive activities of Chlorthalidone.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorthalidone.
SitaxentanChlorthalidone may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Chlorthalidone can be increased when it is combined with Solifenacin.
SotalolThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sotalol.
SpiraprilChlorthalidone may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Spironolactone.
SRT501The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone.
SulfasalazineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorthalidone.
SulpirideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Chlorthalidone.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorthalidone.
TelmisartanChlorthalidone may increase the hypotensive activities of Telmisartan.
TemocaprilChlorthalidone may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Terazosin.
TerbutalineTerbutaline may increase the hypokalemic activities of Chlorthalidone.
TeriflunomideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Teriflunomide.
TerlipressinChlorthalidone may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Chlorthalidone.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Chlorthalidone.
Tiaprofenic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tiaprofenic acid.
TiboloneChlorthalidone may increase the hypotensive activities of Tibolone.
TicrynafenChlorthalidone may increase the hypotensive activities of Ticrynafen.
TimololChlorthalidone may increase the hypotensive activities of Timolol.
TiotropiumThe serum concentration of Chlorthalidone can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Chlorthalidone.
TizanidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tizanidine.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorthalidone.
TolazolineChlorthalidone may increase the hypotensive activities of Tolazoline.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorthalidone.
Tolfenamic AcidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Chlorthalidone.
TolterodineThe serum concentration of Chlorthalidone can be increased when it is combined with Tolterodine.
TopiramateChlorthalidone may increase the hypokalemic activities of Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Chlorthalidone.
ToremifeneChlorthalidone may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorthalidone.
TrandolaprilChlorthalidone may increase the hypotensive activities of Trandolapril.
TranilastThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorthalidone.
TranylcypromineTranylcypromine may increase the hypotensive activities of Chlorthalidone.
TravoprostTravoprost may increase the hypotensive activities of Chlorthalidone.
TrazodoneTrazodone may increase the hyponatremic activities of Chlorthalidone.
TreprostinilChlorthalidone may increase the hypotensive activities of Treprostinil.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Chlorthalidone.
TriamtereneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Triamterene.
TrichlormethiazideChlorthalidone may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe serum concentration of Chlorthalidone can be increased when it is combined with Trihexyphenidyl.
TrimazosinChlorthalidone may increase the hypotensive activities of Trimazosin.
TrimethaphanChlorthalidone may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Chlorthalidone.
TropicamideThe serum concentration of Chlorthalidone can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Chlorthalidone can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Chlorthalidone can be increased when it is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Chlorthalidone.
UmeclidiniumThe serum concentration of Chlorthalidone can be increased when it is combined with Umeclidinium.
UnoprostoneChlorthalidone may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Chlorthalidone.
VardenafilVardenafil may increase the antihypertensive activities of Chlorthalidone.
VecuroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Vecuronium.
VerapamilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.
VilanterolVilanterol may increase the hypokalemic activities of Chlorthalidone.
VilazodoneVilazodone may increase the hyponatremic activities of Chlorthalidone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorthalidone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Chlorthalidone.
VortioxetineVortioxetine may increase the hyponatremic activities of Chlorthalidone.
XylometazolineChlorthalidone may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Chlorthalidone.
ZaltoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Chlorthalidone.
ZomepiracThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zomepirac.
Food Interactions
  • Take with food (increases availability).

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2016 02:17